GREENVILLE, N.C., April 26, 2022 /PRNewswire/ -- Fervent Pharmaceuticals announced today that it has commenced its virtual clinical study to evaluate the effectiveness of its novel product for the treatment of the symptoms of moderate to severe hot flashes, night sweats and nighttime awakenings due to hot flashes. This product is intended to be available, if approved by the FDA, for patients without the need for a prescription. This type of remote study is one of the first of its kind authorized by the FDA. Patients in the study will participate remotely from the comfort of their own homes, where all investigational products will be delivered, and from where all data collection will occur.